Investor Presentation Q1FY23

...set up to deliver sustainable growth trajectory Today - Pegfilgrastim - Trastuzumab - - Bevacizumab (EU) Glargine 100 IU Aspart (EU) BIOCON BIOLOGICS GROWTH DRIVERS < 2 years 2-4 years >4 years - - - Adalimumab (EU) - - Etanercept (EU) Bevacizumab (US) Aspart (US) Adalimumab (US) rH-Insulin (US) Vaccines (SILS collaboration) - - Aflibercept² Ustekinumab Denosumab - Pertuzumab - - Glargine 300 IU Seven undisclosed programs 1 Subject to completion of the acquisition of Covishield Technologies Private Limited (CTPL); 2 Expected to be included in BBL portfolio post the completion of BBL's acquisition of Viatris' biosimilar business (Viatris has global rights to the program partnered with Momenta) -- * Biocon BIOCON LIMITED 21

View entire presentation